早癌检测公司武汉艾米森冲击港股IPO

Core Insights - Wuhan Aimesen Life Science Technology Co., Ltd. is an early-stage cancer detection company established in 2015, focusing on non-invasive testing for liver and urinary tract cancers [1][2] - The company has reported revenues of 6.23 million, 7.24 million, and 6.51 million CNY for the years 2023, 2024, and the first half of 2025, respectively, while incurring net losses of 67.92 million, 38.63 million, and 13.91 million CNY during the same periods [1] - Research and development (R&D) expenses have consistently exceeded revenues, with R&D costs of 22.74 million, 15 million, and 4.52 million CNY for the years 2023, 2024, and the first half of 2025, respectively [1] Company Overview - Wuhan Aimesen has two core products: Aixin Gan for liver cancer and Aiguang Le for urinary tract cancer, with additional products in development for colorectal and esophageal cancers [1] - The company employs 82 staff members as of June 30, 2023, and primarily utilizes a direct sales model, which accounted for 69%, 71%, and 57% of total revenue in 2023, 2024, and the first half of 2025, respectively [2] Customer Concentration - The company has a high customer concentration, with sales to the top five customers accounting for nearly 70% of total sales in 2023. In 2024, the top three customers were Wuhan Aino Medical Laboratory, Jinyu Medical, and Guangdong Kaipu Biological, contributing 52.1%, 9.3%, and 5.2% to total sales, respectively [2]